Markets
Cantor Fitzgerald keeps Neutral rating for Amgen stock
Cantor Fitzgerald has reiterated a Neutral rating and a USD 400.00 price target for Amgen stock. This comes as Amgen announced positive Phase 3 trial results for dazodalibep and reported strong second-quarter earnings that surpassed analyst expectations. Despite these positive developments, the stock is trading below its yearly high, with analyst targets varying significantly.